PubRank

S M Hammer

Author PubWeight™ 113.55‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000 7.81
2 Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000 6.49
3 Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997 6.35
4 Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996 5.29
5 Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998 4.61
6 Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA 1998 4.42
7 The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996 4.03
8 Staphylococcus epidermidis infections. Ann Intern Med 1983 3.57
9 Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 2001 3.28
10 Zidovudine: five years later. Ann Intern Med 1992 2.28
11 Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001 2.08
12 The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program. AIDS 1999 1.70
13 Methylation of the viral genome in an in vitro model of herpes simplex virus latency. Proc Natl Acad Sci U S A 1982 1.56
14 Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000 1.45
15 Infiltration of the lower respiratory tract by helper/inducer T lymphocytes in HTLV-1-associated adult T-cell leukemia/lymphoma. Am J Med 1991 1.43
16 A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia. Aust N Z J Med 2000 1.42
17 Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000 1.42
18 HIV-1 Tat modulates invasion by a bacterial enteric pathogen into a human intestinal cell line. AIDS 1995 1.39
19 In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon. Proc Natl Acad Sci U S A 1986 1.35
20 Cytomegalovirus vasculitis. Case reports and review of the literature. Medicine (Baltimore) 1994 1.24
21 Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. Ann Intern Med 2001 1.24
22 Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature. Rev Infect Dis 1986 1.22
23 The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes. J Virol 1989 1.22
24 Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay. Antimicrob Agents Chemother 1992 1.22
25 Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998 1.20
26 The acute aseptic meningitis syndrome. Infect Dis Clin North Am 1990 1.20
27 Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med 2001 1.18
28 Temporal cluster of herpes simplex encephalitis: investigation by restriction endonuclease cleavage of viral DNA. J Infect Dis 1980 1.17
29 HIV fusion and its inhibition. Antiviral Res 2001 1.13
30 Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses. Ann Intern Med 2001 1.13
31 Activation of human immunodeficiency virus by herpes simplex virus. J Infect Dis 1992 1.13
32 Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 2001 1.09
33 Epstein-Barr virus-induced infectious mononucleosis complicated by acute renal failure: case report and review. Clin Infect Dis 1996 1.05
34 Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis 1998 1.04
35 Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. Osteoporos Int 2010 1.03
36 Ganciclovir therapy of severe cytomegalovirus infections in solid-organ transplant recipients. Transplantation 1988 1.01
37 Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. J Acquir Immune Defic Syndr Hum Retrovirol 1999 0.99
38 Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis 1998 0.96
39 Kinetics of sealing for transient electropores in isolated mammalian skeletal muscle cells. Bioelectromagnetics 1999 0.95
40 Herpes simplex virus infection of human T-cell subpopulations. Infect Immun 1982 0.95
41 Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. Antimicrob Agents Chemother 1994 0.95
42 Physiological effects of HIV infection on human intestinal epithelial cells: an in vitro model for HIV enteropathy. AIDS 1994 0.94
43 Inactivation of human immunodeficiency virus by Betadine products and chlorhexidine. J Acquir Immune Defic Syndr 1989 0.94
44 Antiretroviral therapy: reverse transcriptase inhibition. Antimicrob Agents Chemother 1992 0.92
45 Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. AIDS Res Hum Retroviruses 2000 0.92
46 Effects of recombinant soluble CD4 (rCD4) on HIV-1 infection of monocyte/macrophages. J Infect Dis 1990 0.90
47 Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995 0.90
48 Frequent identification of HIV-1 DNA in bronchoalveolar lavage cells obtained from individuals with the acquired immunodeficiency syndrome. Am Rev Respir Dis 1991 0.90
49 Serologic diagnosis of focal pneumonia caused by Cryptococcus neoformans. Am Rev Respir Dis 1985 0.88
50 Activation and suppression of herpes simplex virus in a human T lymphoid cell line. J Immunol 1981 0.88
51 Antiretroviral resistance testing comes of age. Antivir Ther 2000 0.88
52 Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Infect Dis 2001 0.87
53 Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm. Nat Med 2003 0.86
54 Parasitic sinusitis and otitis in patients infected with human immunodeficiency virus: report of five cases and review. Clin Infect Dis 1997 0.86
55 Viral aseptic meningitis in the United States: clinical features, viral etiologies, and differential diagnosis. Curr Clin Top Infect Dis 1992 0.85
56 Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition. Antimicrob Agents Chemother 1992 0.85
57 Disseminated cryptococcosis diagnosed on peripheral blood smear in a patient with acquired immunodeficiency syndrome. Am J Med 1990 0.85
58 Alpha interferon and acyclovir treatment of herpes simplex virus in lymphoid cell cultures. Antimicrob Agents Chemother 1982 0.84
59 Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical Group 175/801 Study Team. AIDS 1998 0.84
60 Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector. J Virol 1997 0.82
61 Transient and stable ionic permeabilization of isolated skeletal muscle cells after electrical shock. J Burn Care Rehabil 1993 0.82
62 HTLV-III/LAV infection in kidney and liver transplantation. Transplant Proc 1987 0.82
63 Effect of the calcium channel blocker verapamil on human immunodeficiency virus type 1 replication in lymphoid cells. J Infect Dis 1991 0.81
64 Diarrheal disease in patients infected with human immunodeficiency virus in Bangkok, Thailand. Am J Trop Med Hyg 1999 0.80
65 Pulmonary complications of orthotopic liver transplantation. Transplantation 1986 0.80
66 The values of quantitative serum HIV-1 RNA levels and CD4 cell counts for predicting survival time among HIV-positive individuals with CD4 counts of < or = 50 x 10(6) cells/l. AIDS 2000 0.80
67 The pathophysiology of enhanced susceptibility to murine cytomegalovirus respiratory infection during short-term exposure to 5 ppm nitrogen dioxide. Am Rev Respir Dis 1988 0.79
68 Pathogenicity and diversity of HIV and implications for clinical management: a review. J Acquir Immune Defic Syndr 1994 0.78
69 Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group. J Clin Microbiol 1996 0.77
70 Virologic and regimen termination surrogate end points in AIDS clinical trials. JAMA 2001 0.77
71 Herpes simplex virus replication in interleukin-2-stimulated human T cells. J Infect Dis 1985 0.77
72 Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy. Hosp Pract (Off Ed) 1992 0.77
73 Effects of recombinant interleukin-2 on resting human T lymphocytes. J Biol Response Mod 1986 0.77
74 Ganciclovir hepatotoxicity. Pharmacotherapy 1987 0.77
75 Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals. Antivir Ther 1997 0.76
76 Infusion phlebitis associated with a programmable syringe-pump system versus gravity-feed minibottles. Clin Pharm 1987 0.75
77 Isolation of human immunodeficiency virus and serum neutralising antibody. Lancet 1986 0.75
78 In vivo effects of interleukin 3 in HIV type 1-infected patients with cytopenia. AIDS Res Hum Retroviruses 1995 0.75
79 Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1996 0.75
80 An approach to antiretroviral treatment of HIV disease. Nucleoside monotherapy. Hosp Pract (1995) 1995 0.75
81 Infectious complications with the use of cyclosporine versus azathioprine after cadaveric kidney transplantation. Am J Surg 1987 0.75
82 Acyclovir-associated fever: a case report. Pharmacotherapy 1987 0.75
83 Human T-lymphotropic virus type III infection in previously immunocompromised hosts. J Clin Oncol 1986 0.75
84 Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine. AIDS Res Hum Retroviruses 2000 0.75
85 Treatment of HIV infection: the antiretroviral nucleoside analogues. Introduction. Hosp Pract (Off Ed) 1992 0.75